Literature DB >> 9662024

The role of proteolysis during differentiation of Trypanosoma brucei from the bloodstream to the procyclic form.

M C Mutomba1, C C Wang.   

Abstract

The in vitro differentiation of Trypanosoma brucei from bloodstream to procyclic (insect) forms is accompanied by diminishing variant surface glycoprotein (VSG) and increasing levels of procyclin and phosphoenolpyruvate carboxykinase (PEPCK). In this study, we examined the fate of several glycolytic enzymes of T. brucei during differentiation. We observed a down-regulation of glycosomal phosphoglycerate kinase (gPGK) during differentiation. In contrast, intracellular levels of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH), aldolase (ALD), and phosphoglucoisomerase (PGI) remained unchanged during differentiation and apparently continued to be synthesized in the procyclic form. To determine the potential role of proteasomes and other proteases during the differentiation process, we tested the effect of lactacystin, a specific inhibitor of proteasome activity, and morpholinourea-Phe-homoPhe-benz-alpha-pyrone (P27), a selective inhibitor of cysteine proteases, on the in vitro differentiation of T. brucei. Cells differentiated normally in the presence of 1 microM lactacystin, which confirmed our previous observation that this differentiation does not require crossing any phase boundaries in the cell cycle (Mutomba and Wang, Mol Biochem Parasitol 1996;80:89-102). But the cells thus differentiated did not increase in number and retained gPGK. Cells differentiated under 2 microM P27 also proceeded at a normal rate but failed to multiply and retained gPGK. However, most of the differentiated cells under 2 microM P27 also retained VSG on the cell membrane surface and expressed higher levels of procyclin suggesting that a cysteine protease(s) may be involved in releasing VSG and partially reducing procyclin during differentiation. This cysteine protease(s) has been tentatively identified in the procyclic cells as a 48 kDa protein through labeling of cysteine protease(s) with a biotinylated P27 homolog K02 (morpholinourea-Phe-homoPhe-vinylsulfone).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662024     DOI: 10.1016/s0166-6851(98)00012-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  6 in total

1.  Quantitative Proteomic Analysis of Replicative and Nonreplicative Forms Reveals Important Insights into Chromatin Biology of Trypanosoma cruzi.

Authors:  Teresa Cristina Leandro de Jesus; Simone Guedes Calderano; Francisca Nathalia de Luna Vitorino; Ricardo Pariona Llanos; Mariana de Camargo Lopes; Christiane Bezerra de Araújo; Otavio Henrique Thiemann; Marcelo da Silva Reis; Maria Carolina Elias; Julia Pinheiro Chagas da Cunha
Journal:  Mol Cell Proteomics       Date:  2016-11-16       Impact factor: 5.911

2.  Inhibition of proteasome activity blocks Trypanosoma cruzi growth and metacyclogenesis.

Authors:  Josiane Cardoso; Maurilio J Soares; Rubem F S Menna-Barreto; Rozenn Le Bloas; Vanessa Sotomaior; Samuel Goldenberg; Marco A Krieger
Journal:  Parasitol Res       Date:  2008-06-26       Impact factor: 2.289

Review 3.  Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites.

Authors:  Christian Muñoz; Juan San Francisco; Bessy Gutiérrez; Jorge González
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

Review 4.  Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases.

Authors:  Marie-José Bijlmakers
Journal:  Front Chem       Date:  2021-01-28       Impact factor: 5.221

5.  Role of the Trypanosoma brucei natural cysteine peptidase inhibitor ICP in differentiation and virulence.

Authors:  Camila C Santos; Graham H Coombs; Ana Paula C A Lima; Jeremy C Mottram
Journal:  Mol Microbiol       Date:  2007-10-17       Impact factor: 3.501

6.  A function for a specific zinc metalloprotease of African trypanosomes.

Authors:  Paul M Grandgenett; Keiko Otsu; Helen R Wilson; Mary E Wilson; John E Donelson
Journal:  PLoS Pathog       Date:  2007-10-19       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.